APA
Cahir-McFarland E., Ransohoff R. M., Lieberman L. & Plavina T. (082016). CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response. : Neurology.
Chicago
Cahir-McFarland Ellen, Ransohoff Richard M, Lieberman Linda and Plavina Tatiana. 082016. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response. : Neurology.
Harvard
Cahir-McFarland E., Ransohoff R. M., Lieberman L. and Plavina T. (082016). CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response. : Neurology.
MLA
Cahir-McFarland Ellen, Ransohoff Richard M, Lieberman Linda and Plavina Tatiana. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response. : Neurology. 082016.